Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma
ABSTRACT Introduction We report a case in which enfortumab vedotin (EV) therapy was administered as a third‐line treatment for locally advanced bladder cancer (bc), enabling successful radical resection. Case Presentation This report describes the case of a 69‐year‐old male patient with locally adva...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.70019 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT Introduction We report a case in which enfortumab vedotin (EV) therapy was administered as a third‐line treatment for locally advanced bladder cancer (bc), enabling successful radical resection. Case Presentation This report describes the case of a 69‐year‐old male patient with locally advanced bc and pelvic lymph node (LN) metastases. After the failure of first‐line chemotherapy and second‐line immunotherapy, the patient received EV as third‐line treatment. EV therapy resulted in significant tumor reduction, enabling successful radical cystectomy and lymph node dissection (LND). The patient remained recurrence‐free for 22 months post‐surgery. Conclusion EV therapy suggests that it is a promising avenue for further exploration, potentially redefining the therapeutic landscape of historically challenging cases. |
|---|---|
| ISSN: | 2577-171X |